phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"10.37489/2588-0527-2023-1-3-5phgenomics-270Research ArticleОТ ГЛАВНОГО РЕДАКТОРАFROM EDITORБезопасность фармакотерапии 360°: NOLI NOCERE!Pharmacotherapy Safety 360°: NOLI NOCERE!https://orcid.org/0000-0002-4496-3680СычёвД. А.SychevD. A.

д. м. н., профессор, академик РАН, ректор, зав. кафедрой клинической фармакологии и терапии имени академика Б. Е. Вотчала

Dr. Sci. (Med.), professor, Academician of Russian Academy of Sciences, Rector, Head Department of the Clinical Pharmacology and Therapy named after academician B. E. Votchal

dimasychev@mail.ruФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской ФедерацииРоссияRussian Medical Academy of Continuous Professional EducationRussian Federation2023190720230135Copyright © Сычёв Д.А., 20232023Сычёв Д.А.Sychev D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/270

В мае 2023 года на базе ФГБОУ ДПО РМАНПО Минздрава России с успехом прошёл Российский конгресс «Безопасность фармакотерапии 360°: NOLI NOCERE!», который стал высокоуровневой, экспертной площадкой для обсуждения текущих и актуальных вопросов фармаконадзора и безопасности фармакотерапии у различных и особых групп пациентов: в педиатрии, геронтологии и гериатрии, беременных, больных орфанными и онкологическими заболеваниями. Обширная тематика научной программы мероприятия охватила все наиболее значимые аспекты безопасности фармакотерапии в кардиологии, гастроэнтерологии, пульмонологии и аллергологии, эндокринологии, неврологии, онкологии и психиатрии. В обсуждении ключевых задач, которые стоят перед современной наукой, приняли участие более 280 спикеров, модераторов и докладчиков, российских и иностранных экспертов, в числе которых учёные с мировым именем. В работе Конгресса были освещены перспективные для дальнейшего развития биофармацевтики вопросы, связанные с применением искусственного интеллекта и нейросетей.

The Russian Congress «Pharmacotherapy Safety 360°: NOLI NOCERE!» was successfully held at the Russian Ministry of Health in May 2023, providing a high-level, expert platform to discuss current and topical issues of pharmacovigilance and pharmacotherapy safety for different patient groups, including pediatrics, gerontology and geriatrics, pregnant women, patients with orphan and oncological diseases. Extensive scientific topics covered the most significant aspects of the pharmacotherapy safety in various fields, including cardiology, gastroenterology, pulmonology and allergology, endocrinology, neurology, oncology and psychiatry. Over 280 speakers, moderators and lecturers, Russian and foreign experts including world-renowned scientists participated in the discussion of the key tasks facing modern science. The Congress covered issues promising for the further development of biopharmaceuticals, related to the application of artificial intelligence and neural networks.

безопасность лекарствфармаконадзорискусственный интеллектфармакогенетикаdrug safetypharmacovigilanceartificial intelligencepharmacogeneticsReferencesJordan MI, Mitchell TM. Machine learning: Trends, perspectives, and prospects. Science. 2015 Jul 17;349(6245):255–60. DOI: 10.1126/science.aaa8415.Jordan MI, Mitchell TM. Machine learning: Trends, perspectives, and prospects. Science. 2015 Jul 17;349(6245):255–60. DOI: 10.1126/science.aaa8415.Cilluffo G, Fasola S, Ferrante G, Malizia V, Montalbano L, La Grutta S. Machine Learning: An Overview and Applications in Pharmacogenetics. Genes (Basel). 2021 Sep 26;12(10):1511. DOI: 10.3390/genes12101511.Cilluffo G, Fasola S, Ferrante G, Malizia V, Montalbano L, La Grutta S. Machine Learning: An Overview and Applications in Pharmacogenetics. Genes (Basel). 2021 Sep 26;12(10):1511. DOI: 10.3390/genes12101511.Kolluri S, Lin J, Liu R, Zhang Y, Zhang W. Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review. AAPS J. 2022 Jan 4;24(1):19. DOI: 10.1208/s12248-021-00644-3.Kolluri S, Lin J, Liu R, Zhang Y, Zhang W. Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review. AAPS J. 2022 Jan 4;24(1):19. DOI: 10.1208/s12248-021-00644-3.Krishnaveni C, Arvapalli S, Sharma JV. Artificial intelligence in pharma industry-a review. IJIPSR. 2019 Oct 7;7(10):37–50. DOI: 10.21276/IJIPSR.2019.07.10.506Krishnaveni C, Arvapalli S, Sharma JV. Artificial intelligence in pharma industry-a review. IJIPSR. 2019 Oct 7;7(10):37–50. DOI: 10.21276/IJIPSR.2019.07.10.506Garcia-Agundez A, García-Martín E, Eickhoff C. Editorial: The Potential of Machine Learning in Pharmacogenetics, Pharmacogenomics and Pharmacoepidemiology. Front Pharmacol. 2022 May 20;13:928527. DOI: 10.3389/fphar.2022.928527.Garcia-Agundez A, García-Martín E, Eickhoff C. Editorial: The Potential of Machine Learning in Pharmacogenetics, Pharmacogenomics and Pharmacoepidemiology. Front Pharmacol. 2022 May 20;13:928527. DOI: 10.3389/fphar.2022.928527.Zhang L, Tan J, Han D, Zhu H. From machine learning to deep learning: progress in machine intelligence for rational drug discovery. Drug Discov Today. 2017 Nov;22(11):1680–1685. DOI: 10.1016/j.drudis.2017.08.010.Zhang L, Tan J, Han D, Zhu H. From machine learning to deep learning: progress in machine intelligence for rational drug discovery. Drug Discov Today. 2017 Nov;22(11):1680–1685. DOI: 10.1016/j.drudis.2017.08.010.Patel V, Shah M. Artificial intelligence and machine learning in drug discovery and development. Intelligent Medicine. 2022 Aug 1;2(3):134–40.Patel V, Shah M. Artificial intelligence and machine learning in drug discovery and development. Intelligent Medicine. 2022 Aug 1;2(3):134–40.Adam G, Rampášek L, Safikhani Z, Smirnov P, Haibe-Kains B, Goldenberg A. Machine learning approaches to drug response prediction: challenges and recent progress. NPJ Precis Oncol. 2020 Jun 15;4:19. DOI: 10.1038/s41698-020-0122-1.Adam G, Rampášek L, Safikhani Z, Smirnov P, Haibe-Kains B, Goldenberg A. Machine learning approaches to drug response prediction: challenges and recent progress. NPJ Precis Oncol. 2020 Jun 15;4:19. DOI: 10.1038/s41698-020-0122-1.Gerdes H, Casado P, Dokal A, et al. Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs. Nat Commun. 2021 Mar 25;12(1):1850. DOI: 10.1038/s41467-021-22170-8.Gerdes H, Casado P, Dokal A, et al. Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs. Nat Commun. 2021 Mar 25;12(1):1850. DOI: 10.1038/s41467-021-22170-8.Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013 Dec 12;369(24):2294–303. DOI: 10.1056/NEJMoa1311386.Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013 Dec 12;369(24):2294–303. DOI: 10.1056/NEJMoa1311386.Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019 Oct 29;17(1):195. DOI: 10.1186/s12916-019-1426-2.Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019 Oct 29;17(1):195. DOI: 10.1186/s12916-019-1426-2.Wang F, Preininger A. AI in Health: State of the Art, Challenges, and Future Directions. Yearb Med Inform. 2019 Aug;28(1):16–26. DOI: 10.1055/s-0039-1677908.Wang F, Preininger A. AI in Health: State of the Art, Challenges, and Future Directions. Yearb Med Inform. 2019 Aug;28(1):16–26. DOI: 10.1055/s-0039-1677908.Auwerx C, Sadler MC, Reymond A, Kutalik Z. From pharmacogenetics to pharmaco-omics: Milestones and future directions. HGG Adv. 2022 Mar 16;3(2):100100. DOI: 10.1016/j.xhgg.2022.100100.Auwerx C, Sadler MC, Reymond A, Kutalik Z. From pharmacogenetics to pharmaco-omics: Milestones and future directions. HGG Adv. 2022 Mar 16;3(2):100100. DOI: 10.1016/j.xhgg.2022.100100.

The authors declare that there are no conflicts of interest present.